Sharisse Stephenson, MD
Neurology · Bloomington, INNPI 1538358684
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,838 of the $23,334 with a category attached, or 76.4%. AbbVie accounts for 81.1% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2020 at $12,222 and has fallen 98.6% since, to $175 in 2024.
Across 347 payments — averaging $67.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$19K
- Biogen$618
- Amgen$392
- Teva Pharmaceuticals USA, Inc.$325
- Biohaven Pharmaceuticals, Inc.$322
- Biohaven Pharmaceutical Holding Company Ltd.$293
- plus $2K from 32 others
Across 7 payments — averaging $4519.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$32K
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$17,83876%
- Travel & lodging$440%
- Food & beverage$5,15322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $18,918 |
| Biogen | 21 | $618 |
| Amgen(2 entities) | 17 | $392 |
| Teva Pharmaceuticals USA, Inc. | 28 | $325 |
| Biohaven Pharmaceuticals, Inc. | 39 | $322 |
| Biohaven Pharmaceutical Holding Company Ltd. | 35 | $293 |
| Amneal Pharmaceuticals LLC | 18 | $287 |
| Pfizer | 14 | $270 |
| Lilly USA, LLC | 14 | $227 |
| MDD US Operations, LLC | 13 | $224 |
| Upsher-smith Laboratories LLC | 15 | $175 |
| Novartis | 15 | $155 |
| Lundbeck LLC | 6 | $119 |
| SK Life Science, Inc. | 6 | $106 |
| Livanova USA, Inc. | 4 | $105 |
| Neurocrine Biosciences, Inc. | 4 | $78 |
| AstraZeneca | 5 | $78 |
| Genentech USA, Inc. | 3 | $73 |
| UCB, Inc. | 3 | $64 |
| Supernus Pharmaceuticals, Inc. | 4 | $59 |
| Grifols USA, LLC | 3 | $57 |
| Impel Pharmaceuticals Inc. | 2 | $43 |
| Bristol Myers Squibb | 2 | $39 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Abbott | 2 | $28 |
| Almatica Pharma LLC | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Argenx US, Inc. | 1 | $23 |
| GE HealthCare | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
| Sanofi | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Medicomp Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,334 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 16 | $194,760 |
| AustedoDeutetrabenazine | 13 | $71,405 |
| UbrelvyUbrogepant | 34 | $43,408 |
| Nurtec OdtRimegepant Sulfate | 38 | $42,693 |
| BotoxOnabotulinumtoxina | 16 | $23,808 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $21,908 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $15,322 |
| Zolmitriptan | 22 | $14,390 |
| Lacosamide | 41 | $9,107 |
| Levetiracetam | 76 | $5,787 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 103 | $3,092 |
| Memantine Hcl | 70 | $2,852 |
| Gabapentin | 110 | $2,708 |
| Levetiracetam ErLevetiracetam | 38 | $2,135 |
| Lamotrigine ErLamotrigine | 12 | $2,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $57 | $194,76016 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $325 | $71,40513 claims |
| AbbVieUbrelvy, Botox | $18,918 | $67,21550 claims |
| PfizerNurtec Odt | $270 | $42,69338 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $35 | $21,90812 claims |
| Upsher-smith Laboratories LLCTopiramate | $175 | $1,85693 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.
Other neurology in Bloomington
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
- Marlene BultemeyerFort Wayne$277K
- Jerry SmarttCarmel$254K
- Andrea HallerFort Wayne$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.